Any current/future new fundraising through debt or equity?

The company reported a healthy balance sheet with an improved debt-equity ratio of 0.55 as of H1 FY26, down from 0.59 at the start of the year. There was no explicit mention of any planned new fundraising through debt or equity in the Q2 FY26 earnings call. Capital expenditure guidance for the full year remains at Rs. 200 crores, focused on high-ROI projects, funded through disciplined capital allocation. Finance costs for Q2 FY26 reduced by 13%-20% YoY, indicating effective management of existing debt. No announcements or indications were made regarding fresh debt or equity issuances during t

Any current/future capex/capital investment/strategic investment?

Capital expenditure (CAPEX) in H1 FY 2026 stood at Rs. 65 crores, focused on debottlenecking, regulatory upgrades, and expanding CDMO capacity. Full-year CAPEX guidance is maintained at Rs. 200 crores, emphasizing disciplined allocation toward high ROI projects aligned with long-term growth strategy. Investments include repurposing a large plant from specialty chemicals to fully pharma assets, with Phase 1 completing by end FY 2026 and Phase 2 by end calendar year, enabling capacity for new molecules. New pilot-scale capacity is being set up at the Pune R&D center to support growth in food and

Future growth expectations in sales/revenue/volumes?

Expect strong recovery in H2 FY26 with ramp-up in deliveries post-US FDA remediation (Page 4, 13). Aim to hold full-year guidance of double-digit growth in pharma despite 1H challenges (Page 14). New molecules and product launches projected annually (2-3 new products) supporting medium-term growth (Page 6). Robust development pipelines with 8-9 molecules progressing well; peak food and nutraceutical output expected in 18-24 months (Page 6). Increasing CDMO early-stage RFPs and transitioning projects from development to pilot scale (Page 6). Crop protection volumes starting to recover; flat sal

Future growth expectations in earnings/operating earnings/profits/EPS?

Hikal expects a strong recovery in H2 FY26, with resumed deliveries and ramp-up in pharmaceutical business following resolution of US FDA warning letter issues. Full-year double-digit growth in pharma is still the guidance, with deferred sales mainly shifted to H2 FY26. Development revenue from new customers is anticipated to grow, with potential scale-up as molecules progress to market. Crop protection segment expected to have stable performance and gradual volume recovery, though margins remain under pressure due to pricing challenges. New investments in high-potency and specialty ch

Current/ Expected Orderbook/ Pending Orders?

The company has seen several inquiries and RFPs from both mid-size and small-size companies, especially in the pharma CDMO segment. Approximately $4 to $5 million in development revenue is expected from these new customers in the current year, with potential for scaling up. The RFP conversion rate is typically between 15% to 20%, with plans to improve this to 20%-25% through enhanced BD efforts. In the animal health segment, pre-commercial quantities are being supplied with registrations progressing; growth is anticipated as registrations complete. No cancellations of existing purchase orders

IN US

Sale is live|00:00:00left today

Hikal LtdQ3 FY25Pharmaceuticals & Biotechnology

Hikal Ltd Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹218P/E: 103.9Market Cap: ₹2.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Expect strong recovery in H2 FY26 with ramp-up in deliveries post-US FDA remediation (Page 4, 13).
→Aim to hold full-year guidance of double-digit growth in pharma despite 1H challenges (Page 14).
→New molecules and product launches projected annually (2-3 new products) supporting medium-term growth (Page 6).
→Robust development pipelines with 8-9 molecules progressing well; peak food and nutraceutical output expected in 18-24 months (Page 6).
→Increasing CDMO early-stage RFPs and transitioning projects from development to pilot scale (Page 6).
→Crop protection volumes starting to recover; flat sales expected full year (Page 5).
→Animal health segment to ramp up commercial supplies over next 1-2 quarters with strong development pipeline (Pages 5, 21).
→Investment in new capabilities and high-potency labs to support future growth in niche segments like oncology APIs (Pages 5, 21).
→Conversion rate of pharma RFPs improving, with expected scale-up of development revenues (Page 16).

Margin guidance

Category 3

→Hikal expects a strong recovery in H2 FY26, with resumed deliveries and ramp-up in pharmaceutical business following resolution of US FDA warning letter issues.
→Full-year double-digit growth in pharma is still the guidance, with deferred sales mainly shifted to H2 FY26.
→Development revenue from new customers is anticipated to grow, with potential scale-up as molecules progress to market.
→Crop protection segment expected to have stable performance and gradual volume recovery, though margins remain under pressure due to pricing challenges.
→New investments in high-potency and specialty chemicals labs aim to drive innovation and higher-margin revenues in the mid- to long-term.
→Conversion rate for pharma RFPs is around 15-20%, expected to improve to 20-25% with increased business development efforts.
→Overall, Hikal remains optimistic about long-term growth through portfolio diversification, global partnerships, and compliance strengthening, but short-term earnings impacted by regulatory challenges.

3 more insights locked — sign up free to unlock

Fundraise plans

→The company reported a healthy balance sheet with an improved debt-equity ratio of 0.55 as of H1 FY26, down from 0.59 at the start of the year.
→There was no explicit mention of any planned new fundraising through debt or equity in the Q2 FY26 earnings call.
→Capital expenditure guidance for the full year remains at Rs. 200 crores, focused on high-ROI projects, funded through disciplined capital allocation.
→Finance costs for Q2 FY26 reduced by 13%-20% YoY, indicating effective management of existing debt.
→No announcements or indications were made regarding fresh debt or equity issuances during the call or in the documented material.

Order book

Yes

→The company has seen several inquiries and RFPs from both mid-size and small-size companies, especially in the pharma CDMO segment.
→Approximately $4 to $5 million in development revenue is expected from these new customers in the current year, with potential for scaling up.
→The RFP conversion rate is typically between 15% to 20%, with plans to improve this to 20%-25% through enhanced BD efforts.
→In the animal health segment, pre-commercial quantities are being supplied with registrations progressing; growth is anticipated as registrations complete.
→No cancellations of existing purchase orders were reported despite regulatory challenges; some sales deferred but expected to be fulfilled soon.
→Several new development contracts and shortlisted RFPs indicate a strong and diversified project pipeline.

Capex plans

Yes

→Capital expenditure (CAPEX) in H1 FY 2026 stood at Rs. 65 crores, focused on debottlenecking, regulatory upgrades, and expanding CDMO capacity.
→Full-year CAPEX guidance is maintained at Rs. 200 crores, emphasizing disciplined allocation toward high ROI projects aligned with long-term growth strategy.
→Investments include repurposing a large plant from specialty chemicals to fully pharma assets, with Phase 1 completing by end FY 2026 and Phase 2 by end calendar year, enabling capacity for new molecules.
→New pilot-scale capacity is being set up at the Pune R&D center to support growth in food and nutraceutical ingredients.
→Investment in a High Potent Active Pharma Ingredient (HP API) lab to enter rapidly growing segments like Oncology APIs.
→Ongoing efforts include remediation CAPEX to comply with FDA requirements at Bangalore facility.
→Expansion of business development manpower globally to capitalize on new opportunities.

How does Hikal Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Hikal Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Hikal Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio